ROSETTA Breast 01: The effects and safety of pumitamig in patients with triple-negative breast cancer

This study explores how individuals with triple‑negative breast cancer (TNBC) respond to the investigational treatment pumitamig. TNBC is a biologically distinct form of breast cancer that lacks hormone receptor expression and HER2 amplification, which limits the number of available targeted treatment options. Researchers are studying how pumitamig affects tumor response, side effects, symptom patterns, and overall treatment experience to help expand understanding of TNBC and potential new therapeutic options.

 

Disclaimer: This summary is intended solely for informational purposes. It does not provide medical advice, imply effectiveness, or promote participation. Individuals with TNBC should speak with a healthcare provider for guidance.